54.31
-0.37 (-0.68%)
| Previous Close | 54.68 |
| Volume | 394,069 |
| Price / Earnings (Forward) | 19.12 |
| Price / Sales | 6.65 |
| Price / Book | 127.01 |
| 52 Weeks Range |
| Profit Margin | -125.70% |
| Operating Margin (TTM) | -99.16% |
| Diluted EPS (TTM) | -4.76 |
| Quarterly Revenue Growth (YOY) | 286.80% |
| Total Debt/Equity (MRQ) | 1,016.89% |
| Current Ratio (MRQ) | 8.25 |
| Operating Cash Flow (TTM) | -108.78 M |
| Levered Free Cash Flow (TTM) | -60.04 M |
| Return on Assets (TTM) | -15.14% |
| Return on Equity (TTM) | -343.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | AnaptysBio, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | -0.5 |
| Average | -1.17 |
|
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 5.09% |
| % Held by Institutions | 133.99% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |